AstraZeneca Remedy Reduces Severe Covid-19 Cases In Testing

The trial is the first in phase III to demonstrate a benefit in both the prophylaxis and treatment of Covid-19. | Photo: Bigstock

A drug in the experimental phase developed by AstraZeneca reduces the risk of contracting serious diseases or dying from Covid-19 by 50%, as the British pharmaceutical company revealed on Monday (11).

Follow Semper Familia on Instagram!

In a statement, the company presented the results of the latest phase of a trial showing that AZD7442, a combination of antibodies, achieved a “statistically significant” reduction in severe cases or death from Covid-19 , compared to placebo administered on an outpatient basis with mild to moderate symptoms of the virus. About 90% of the study participants were from populations at high risk for progression to severe disease.

The study found that a 600 milligram dose of AZD7442 given by intramuscular injection reduced the risk of developing serious illness or even death by 50% compared to symptomatic patients who took a placebo for seven days or less. .

In participants who received treatment within five days of symptom onset, AZD7442 reduced the risk of developing serious illness or dying by 67% compared to patients on placebo.

This trial with AZD7442 is the first Phase III trial to demonstrate benefit in both prophylaxis and treatment of Covid-19 and is easily administered by injection, notes AstraZeneca.

“With persistent cases of serious Covid-19 infections around the world, there is a significant need for new therapies such as AZD7442, which can be used to protect vulnerable populations from covid-19 infection and can also help prevent progression to serious illness. “said Hugh Montgomery, professor of intensive care at University College London and principal investigator of the Tackle trial.

These positive results show that “a practical intramuscular dose of AZD7442 can play an important role in the fight against this devastating pandemic”, he added.

In turn, Mene Pangalos, executive vice president of the pharmaceutical company, pointed out that these AZD7442 results add to the evidence that exists for the use of this therapy in both the prevention and treatment of Covid-19.

“Early intervention with our antibody (AZD7442) can allow a significant reduction in the progression to serious disease, with continued protection for more than six months,” Pangalos pointed out.

Back to top button